Zobrazeno 1 - 10
of 26
pro vyhledávání: '"J C, Yau"'
Publikováno v:
Annals of Oncology. 14:1744-1750
Background: While adjuvant chemotherapy is known to improve survival in older women with breast cancer, there is little information about its effects on physical function and health-related quality of life. Patients and methods: ‘Young’ (
Publikováno v:
Cereal Chemistry Journal. 76:668-672
Nonzein proteins were analyzed using SDS-PAGE to study their relationship to lysine level in mature endosperm of three isogenic lines and 29 inbred lines. The majority of nonzein proteins are glutelins that contain a relatively high lysine content. T
Autor:
Frank R. Dunphy, J C Yau, BS Andersson, V. Spencer, J Hester, Gary Spitzer, C F LeMaistre, K Dicke, R O Wallerstein, SD Huan
Publikováno v:
Blood. 79:3388-3393
Peripheral blood cells (PBC) can hasten hematopoietic recovery after high-dose chemotherapy. To determine if PBC apheresed after mobilization further enhance hematopoietic recovery over that achieved with autologous bone marrow (ABM) and recombinant
Publikováno v:
Poultry Science. 70:167-172
Safflower (79% linoleic acid), olive (70% oleic acid), and coconut (83% saturated fatty acids) oils were each fed to broilers at 8% of the diet to evaluate the possibility of enriching the levels of specific fatty acids in broiler breast and adipose
Publikováno v:
Oncology reports. 5(6)
Decreased expression of the transmembrane 4 superfamily member, CD9, is associated with poor prognosis in patients with breast or non-small cell lung cancer. The expression of CD9 in lymphoma was examined in this study. Fifty-one sections with diffus
Autor:
J C, Yau, C, Germond, S, Gluck, C, Cripps, S, Verma, B F, Burns, T M, Koski, D C, Lister, G D, Goss
Publikováno v:
American journal of hematology. 59(2)
Elderly patients with intermediate- or high-grade non-Hodgkin's lymphoma have a worse outcome than those who are younger than 60 years. It has been shown that aggressive combination chemotherapy is poorly tolerated in older patients resulting in a su
Autor:
J C, Yau, J A, Neidhart, P, Triozzi, S, Verma, J, Nemunaitis, D P, Quick, D G, Mayernik, D H, Oette, F A, Haynes, J, Holcenberg
Publikováno v:
American journal of hematology. 51(4)
This is a double-blind randomized placebo-controlled trial to evaluate the efficacy and safety of granulocyte-macrophage colony-stimulating-factor (GM-CSF) after dose-intensive cyclophosphamide, etoposide, and cisplatin (DICEP). Fifty-six patients wi
Publikováno v:
European Journal of Cancer Supplements. 1:S121-S122
Autor:
F R, Dunphy, G, Spitzer, J E, Fornoff, J C, Yau, S D, Huan, K A, Dicke, A U, Buzdar, G N, Hortobagyi
Publikováno v:
Cancer. 73(8)
Poor prognosis of Stage IV breast cancer patients have at best a 10% 3-year survival rate with conventional chemotherapy. Dose-intensive chemotherapy improved survival rates for some of these patients.All patients were Stage IV estrogen receptor-nega
Autor:
S D, Huan, J, Hester, G, Spitzer, J C, Yau, F R, Dunphy, R O, Wallerstein, K, Dicke, V, Spencer, C F, LeMaistre, B S, Andersson
Publikováno v:
Blood. 79(12)
Peripheral blood cells (PBC) can hasten hematopoietic recovery after high-dose chemotherapy. To determine if PBC apheresed after mobilization further enhance hematopoietic recovery over that achieved with autologous bone marrow (ABM) and recombinant